Pfizer loses heart for cardiovascular research
This article was originally published in Scrip
Executive Summary
Pfizer will end early-stage development of cardiovascular treatments as part of a broad restructuring of its research programmes. Research into CV therapies, which have been the bastion of the company's business, will be abandoned in favour of more profitable areas, such as oncology therapies.